Researchers from the University of Western Ontario provide a better understanding of why some people seem to become hooked with their first smoke and nicotine.
The research, led by Steven Laviolette of the Department of Anatomy and Cell Biology at the Schulich School of Medicine & Dentistry, could lead to new therapies to prevent nicotine dependence and to help smokers trying to quit.
The paper was published today in Journal of Neuroscience.
“Nicotine interacts with a variety of neurochemical pathways within the brain to produce its rewarding and addictive effects,” explains Laviolette.
“However, during the early phase of tobacco exposure, many individuals find nicotine highly unpleasant and aversive, whereas others may become rapidly dependent on nicotine and find it highly rewarding. We wanted to explore that difference.”
The researchers found one brain pathway in particular uses the neurotransmitter dopamine to transmit signals related to nicotine’s rewarding properties. This pathway is called the mesolimbic dopamine system and is involved in the addictive properties of many drugs of abuse, including cocaine, alcohol and nicotine.
“While much progress has been made in understanding how the brain processes the rewarding effects of nicotine after the dependence is established, very little is known about how the mesolimbic dopamine system may control the initial vulnerability to nicotine; that is, why do some individuals become quickly addicted to nicotine while others do not, and in some cases, even find nicotine to be highly aversive.”
Scientists identified which specific dopamine receptor subtype controlled the brain’s initial sensitivity to nicotine’s rewarding and addictive properties. They were able to manipulate the receptors to control whether the nicotine was processed as rewarding or aversive.
“Importantly, our findings may explain an individual’s vulnerability to nicotine addiction, and may point to new pharmacological treatments for the prevention of it, and the treatment of nicotine withdrawal,” says Laviolette.
The research was funded by the Canadian Institutes of Health Research and the Canadian Psychiatric Research Foundation.
Source: University of Western Ontario, Canada